NCT04862780 2025-02-10(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCBlueprint Medicines CorporationPhase 1 Terminated177 enrolled
NCT05241873 2025-02-10(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsBlueprint Medicines CorporationPhase 1 Terminated103 enrolled
NCT05153408 2023-06-18(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCBlueprint Medicines CorporationPhase 1 Terminated20 enrolled
NCT02543645 2018-04-30A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerCelldex TherapeuticsPhase 1 Terminated18 enrolled